Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-DATA: Sequential IDH-targeted vs Non-targeted Therapy in Newly Diagnosed IDH-mutated AML
NCT05401097Phase 2Recruiting
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivosidenib, enasidenib and venetoclax in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Overall treatment failure at 12 months. Started Sep 2022; status: recruiting.
02
Drugs
ivosidenibenasidenibvenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05401097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401097.